Saturday 17 October 2026
Export VVOS’s income statement to Excel — free account
Vivos Therapeutics, Inc.
VVOS Healthcare Medical Devices
Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 34.9%, EPS grew 43.6%, free cash flow grew 16.4% and total debt rose 2.79%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.13
0.01
−7.14%
Follow VVOS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.96 | 1.20 | 0.88 | 0.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.17) | (5.47) | (2.87) | (2.58) | |
P/B ratio |
13.42 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.29 | 1.59 | 1.17 | 0.69 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.75) | (1.81) | (1.31) | (0.85) | |
EV/FCF |
(2.58) | (1.57) | (1.16) | (0.76) | |
Quick Ratio |
0.70 | 0.20 | 0.22 | 0.16 | |
Current Ratio |
0.78 | 0.24 | 0.27 | 0.21 | |
Net Debt/EBITDA |
(1.29) | (1.14) | (0.91) | (1.48) | |
Debt/Assets |
34.00% | 35.07% | 30.81% | 33.71% | |
Debt/Equity |
3.44 | (5.69) | (6.09) | (2.04) | |
Asset Turnover |
0.84 | 0.86 | 1.08 | 0.83 | |
Operating CF/Net income |
0.77 | 0.55 | 0.78 | 0.57 | |
Capex/Depreciation |
0.22 | (3.46) | (0.04) | (0.81) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
122.17% | 233.29% | 179.34% | 141.04% | |
Intangible Assets out of Total Assets |
0.41 | 0.50 | 0.50 | 0.51 | |
Share Based Compensation of Revenue |
0.81% | 1.23% | 12.94% | 2.37% | |
Graham Net Nets |
(0.51) | (1.07) | (1.24) | (2.94) | |
Graham Number |
0.00 | 2.65 | 1.82 | 3.51 | |
Earnings Yield |
(57.10%) | (101.97%) | (181.36%) | (413.04%) | |
Free Cash Flow Yield |
(45.21%) | (84.41%) | (114.16%) | (233.76%) | |
Revenue per Share |
0.62 | 0.37 | 0.35 | 0.29 | |
Operating CF per Share |
(0.38) | (0.37) | (0.41) | (0.18) | |
Capex per Share |
0.01 | (0.15) | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.37) | (0.52) | (0.41) | (0.20) | |
Cash per Share |
0.28 | 0.20 | 0.14 | 0.10 | |
Shareholders Equity per Share |
0.23 | (0.15) | (0.09) | (0.23) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.23 | (0.15) | (0.09) | (0.23) | |
Free Cash Flow |
(4.08) | (5.34) | (6.03) | (3.56) | |
Working Capital |
(1.65) | (13.69) | (13.12) | (16.18) | |
Capital Expenditures |
0.08 | (1.53) | (0.02) | (0.42) | |
Net Current Asset Value |
(17.33) | (22.32) | (21.49) | (23.92) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | 0.40 | 0.00 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.29 | 1.01 | 1.24 | 1.54 | |
Average Payables |
1.59 | 1.39 | 1.60 | 2.35 | |
Average Assets |
20.50 | 20.22 | 18.16 | 25.09 | |
Average Common Equity |
5.10 | 3.20 | 1.70 | (0.25) |
Columns are period end dates